Anaveon
PrivateLast Round
Series B
Dec 16, 2021
Est. Valuation
$248.5M
Total Funding Raised
$155.17M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Anaveon operates in Healthcare & Life Sciences and is based in Basel. Its latest recorded funding round was a Series B round in December 2021.
Anaveon is a biotechnology company that develops next-generation precision biologics designed to selectively modulate the immune system for the treatment of autoimmune and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Anaveon Comparables
Compare Anaveon with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Synthekine | 83% | |
| Aulos Bioscience | 80% | |
| Audax Biosciences | 79% |
For institutional investors. Book with your work email.
Anaveon Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 16, 2021 | ||||
| Series A | Feb 26, 2019 | ||||
| Grant | Dec 1, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Anaveon Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series B |
| Forbion | Series B |
| Syncona | Series B, Series A |
| Pontifax Venture Capital | Series B |
| Pontifax Credit | Series B |
| TD Securities | Series B |
| Blue Owl Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 303% MoM, from 524 to 2.1K.
- Mar 23, 2026
Thaminda Ramanayake appointed as new Chief Executive Officer.
For institutional investors. Book with your work email.
Anaveon Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Anaveon's valuation, stock price, and market status.
Is Anaveon a public or private company?
Anaveon is a private company.
What is the current stock price of Anaveon?
Anaveon is a private company, so its shares have no public market price. Caplight tracks Anaveon's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Anaveon worth (valuation)?
Anaveon's valuation is estimated at $248.5M based on funding round data.
Can I buy Anaveon stock?
Anaveon shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Anaveon's last funding round?
Anaveon's most recent funding round was Series B on December 16, 2021.
Who are the main investors in Anaveon?
Key investors in Anaveon include Forbion Capital Partners, Forbion, Syncona.
Will Anaveon IPO soon?
No public IPO plans have been announced for Anaveon.
How can I track Anaveon secondary market activity?
Caplight tracks bids, offers, and trades in Anaveon's shares on secondary markets.